Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Biologic agents in the management of Hodgkin lymphoma
Armin Rashidi
, Nancy L. Bartlett
Medicine - Hematology, Oncology, Transplant
Research output
:
Contribution to journal
›
Review article
›
peer-review
5
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Biologic agents in the management of Hodgkin lymphoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Hodgkin Lymphoma
100%
Biological Agents
100%
Biologic Therapy
75%
Antibody-drug Conjugate
50%
Checkpoint Inhibitors
50%
Hematological Malignancies
25%
Translational Research
25%
In Cancer
25%
Clinical Research
25%
Monoclonal Antibody
25%
Treatment Options
25%
Classical Hodgkin Lymphoma
25%
Oncology
25%
Immunotoxin
25%
Tumor Malignancy
25%
Chimeric Antigen Receptor T Cells (CAR-T)
25%
Immunomodulator
25%
Radioimmunotherapy
25%
Durable Remission
25%
Refractory Disease
25%
Adoptive Immunotherapy
25%
Therapeutic Monoclonal Antibody
25%
Armamentarium
25%
Cancer Therapeutics
25%
T Cell Inhibitors
25%
Solid Tumor Therapy
25%
Multiple Relapses
25%
Medicine and Dentistry
Hodgkin's Lymphoma
100%
Biological Therapy
75%
Antibody-Drug Conjugate
50%
Monoclonal Antibody
50%
Biological Product
25%
Malignant Neoplasm
25%
Oncology
25%
Clinical Research
25%
Classical Hodgkin Lymphoma
25%
Solid Malignant Neoplasm
25%
Translational Research
25%
Hematologic Malignancy
25%
Chimeric Antigen Receptor T-Cell
25%
Immunotoxin
25%
Adoptive Immunotherapy
25%
Immunomodulating Agent
25%
Radioimmunotherapy
25%
Diseases
25%
Treatment Option
25%